165 related articles for article (PubMed ID: 35387690)
1. Are anti-glutamic acid decarboxylase 65-kDa isoform antibodies related to diabetes or brain tumor?
Maimaiti B; Mijiti S; Sun H; Xie Y; Jiang T; Meng Q; Meng H
Eur J Med Res; 2022 Apr; 27(1):53. PubMed ID: 35387690
[TBL] [Abstract][Full Text] [Related]
2. A case report of anti-GAD65 antibody-positive autoimmune encephalitis in children associated with autoimmune polyendocrine syndrome type-II and literature review.
Sapana T; Li W; Tian F; Yan W; Dou B; Hua S; Zhuo Z
Front Immunol; 2023; 14():1274672. PubMed ID: 38077387
[TBL] [Abstract][Full Text] [Related]
3. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.
Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M
Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus.
Walikonis JE; Lennon VA
Mayo Clin Proc; 1998 Dec; 73(12):1161-6. PubMed ID: 9868413
[TBL] [Abstract][Full Text] [Related]
5. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
Ali F; Rowley M; Jayakrishnan B; Teuber S; Gershwin ME; Mackay IR
J Autoimmun; 2011 Sep; 37(2):79-87. PubMed ID: 21680149
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
8. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
[TBL] [Abstract][Full Text] [Related]
9. GAD65 neurological autoimmunity.
McKeon A; Tracy JA
Muscle Nerve; 2017 Jul; 56(1):15-27. PubMed ID: 28063151
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic anti-GAD65 extralimbic encephalitis presented with epilepsy: A case report.
Xia SQ; Fan HN; Fan LF; Xia W; Chen G
Medicine (Baltimore); 2023 Nov; 102(44):e34780. PubMed ID: 37933077
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of glutamic acid decarboxylase (GAD) 65 antibody detection methods for neurological and diabetic investigation in an Australian diagnostic laboratory.
Cecchin A; Reynolds C; Ali S; Hissaria P
Pathology; 2023 Jun; 55(4):538-542. PubMed ID: 37037719
[TBL] [Abstract][Full Text] [Related]
13. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?
Lacruz Ballester L; Fernandez-Fournier M; Puertas Muñoz I; Rodriguez Fraga O; Lastras Fernandez-Escandon C; Rodriguez de Rivera Garrido FJ; Alba Suarez EM; Tallon Barranco A
Neurol Sci; 2022 Jan; 43(1):633-641. PubMed ID: 33914193
[TBL] [Abstract][Full Text] [Related]
14. Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.
Hampe CS; Radtke JR; Wester A; Carlsson A; Cedervall E; Jönsson B; Ivarsson SA; Elding Larsson H; Larsson K; Lindberg B; Neiderud J; Rolandsson O; Lernmark Å
Diabet Med; 2019 Nov; 36(11):1375-1383. PubMed ID: 30264481
[TBL] [Abstract][Full Text] [Related]
15. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes.
Ziegler B; Strebelow M; Rjasanowski I; Schlosser M; Ziegler M
Autoimmunity; 1998; 28(2):61-8. PubMed ID: 9771977
[TBL] [Abstract][Full Text] [Related]
17. Quantitative brain imaging analysis of neurological syndromes associated with anti-GAD antibodies.
Dade M; Giry M; Berzero G; Benazra M; Huberfeld G; Leclercq D; Navarro V; Delattre JY; Psimaras D; Alentorn A
Neuroimage Clin; 2021; 32():102826. PubMed ID: 34563986
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
19. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Manto M; Mitoma H; Hampe CS
Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
[TBL] [Abstract][Full Text] [Related]
20. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
